ID

34993

Beskrivning

MM-302 Plus Trastuzumab vs. Chemotherapy of Physician's Choice Plus Trastuzumab in HER2-Positive Locally Advanced/Metastatic Breast Cancer Patients; ODM derived from: https://clinicaltrials.gov/show/NCT02213744

Länk

https://clinicaltrials.gov/show/NCT02213744

Nyckelord

Versioner (1)
  1. 2019-02-07 2019-02-07 -
Rättsinnehavare

See clinicaltrials.gov

Uppladdad den

7 februari 2019

DOI

För en begäran logga in.

Licens

Creative Commons BY 4.0
Modellkommentarer :

Här kan du kommentera modellen. Med hjälp av pratbubblor i Item-grupperna och Item kan du lägga in specifika kommentarer.

Tillbaka till modellkommentarer
Itemgroup-kommentar för :

Item-kommentar för :

Du måste vara inloggad för att kunna ladda ner formulär. Var vänlig logga in eller registrera dig utan kostnad.

Eligibility Breast Cancer NCT02213744

Engelsk

Eligibility Breast Cancer NCT02213744

1 Formulär  
Inclusion Criteria
Beskrivning

Inclusion Criteria

Alias
UMLS CUI
C1512693
patients must have histologically or cytologically confirmed invasive cancer of the breast
Beskrivning

Invasive carcinoma of breast

Datatyp

boolean

Alias
UMLS CUI [1]
C0853879
patients must have documented locally advanced/metastatic disease, defined by the investigator, which is not amenable to resection with curative intent.
Beskrivning

Advanced disease Locally | Neoplasm Metastasis | Excision Curative intent Unsuccessful

Datatyp

boolean

Alias
UMLS CUI [1,1]
C0679246
UMLS CUI [1,2]
C1517927
UMLS CUI [2]
C0027627
UMLS CUI [3,1]
C0728940
UMLS CUI [3,2]
C1276305
UMLS CUI [3,3]
C1272705
patients must have her2-positive breast cancer as defined by asco/cap 2013 guidelines that is confirmed by a sponsor-designated central laboratory
Beskrivning

HER2-positive carcinoma of breast

Datatyp

boolean

Alias
UMLS CUI [1]
C1960398
patients must have progressed on, or be intolerant to pertuzumab in the labc/mbc setting
Beskrivning

Disease Progression | Intolerance to Pertuzumab

Datatyp

boolean

Alias
UMLS CUI [1]
C0242656
UMLS CUI [2,1]
C1744706
UMLS CUI [2,2]
C1328025
patients must have progressed on, or be intolerant to ado-trastuzumab emtansine in the labc/mbc setting
Beskrivning

Disease Progression | Intolerance to Ado-trastuzumab emtansine

Datatyp

boolean

Alias
UMLS CUI [1]
C0242656
UMLS CUI [2,1]
C1744706
UMLS CUI [2,2]
C2935436
patients must have been previously treated with trastuzumab in any setting (which may have been previously administered with or without pertuzumab)
Beskrivning

Trastuzumab Previous | Pertuzumab Previous

Datatyp

boolean

Alias
UMLS CUI [1,1]
C0728747
UMLS CUI [1,2]
C0205156
UMLS CUI [2,1]
C1328025
UMLS CUI [2,2]
C0205156
ecog performance status of 0 or 1
Beskrivning

ECOG performance status

Datatyp

boolean

Alias
UMLS CUI [1]
C1520224
Exclusion Criteria
Beskrivning

Exclusion Criteria

Alias
UMLS CUI
C0680251
patients who have previously been treated with doxorubicin, liposomal doxorubicin, epirubicin, mitoxantrone, or any other anthracycline derivative
Beskrivning

Doxorubicin | doxorubicin liposome | Epirubicin | Mitoxantrone | Anthracycline Derivative

Datatyp

boolean

Alias
UMLS CUI [1]
C0013089
UMLS CUI [2]
C0717726
UMLS CUI [3]
C0014582
UMLS CUI [4]
C0026259
UMLS CUI [5,1]
C0282564
UMLS CUI [5,2]
C1527240
subjects with central nervous system (cns) metastases, unless they have been treated and are stable without symptoms for 4 weeks after completion of treatment and must be off steroids for at least 4 weeks prior to enrollment
Beskrivning

CNS metastases | Exception Treatment completed | Exception Stable status Without Symptoms | Exception Steroids Absent

Datatyp

boolean

Alias
UMLS CUI [1]
C0686377
UMLS CUI [2,1]
C1705847
UMLS CUI [2,2]
C0580352
UMLS CUI [3,1]
C1705847
UMLS CUI [3,2]
C0205360
UMLS CUI [3,3]
C0332288
UMLS CUI [3,4]
C1457887
UMLS CUI [4,1]
C1705847
UMLS CUI [4,2]
C0038317
UMLS CUI [4,3]
C0332197
patients with any class of new york heart association (nyha) chf or heart failure with preserved ejection fraction (hfpef)
Beskrivning

Congestive heart failure New York Heart Association Classification | Heart failure with preserved ejection fraction [HFpEF]

Datatyp

boolean

Alias
UMLS CUI [1,1]
C0018802
UMLS CUI [1,2]
C1275491
UMLS CUI [2]
C4509226
patients with a history of known coronary artery disease or a myocardial infarction within the last 12 months
Beskrivning

Coronary Artery Disease | Myocardial Infarction

Datatyp

boolean

Alias
UMLS CUI [1]
C1956346
UMLS CUI [2]
C0027051
patients with a known history of serious cardiac arrhythmias requiring treatment (exception: controlled atrial fibrillation, paroxysmal supraventricular tachycardia)
Beskrivning

Cardiac Arrhythmia Serious Treatment required for | Exception Controlled atrial fibrillation | Exception Paroxysmal supraventricular tachycardia

Datatyp

boolean

Alias
UMLS CUI [1,1]
C0003811
UMLS CUI [1,2]
C0205404
UMLS CUI [1,3]
C0332121
UMLS CUI [2,1]
C1705847
UMLS CUI [2,2]
C0577699
UMLS CUI [3,1]
C1705847
UMLS CUI [3,2]
C0030590
patients who previously discontinued trastuzumab due to unacceptable cardiac toxicity
Beskrivning

Trastuzumab Discontinued Due to Cardiotoxicity

Datatyp

boolean

Alias
UMLS CUI [1,1]
C0728747
UMLS CUI [1,2]
C1444662
UMLS CUI [1,3]
C0678226
UMLS CUI [1,4]
C0876994
patients with a history of lvef decline to below 50% during or after prior trastuzumab/lapatinib or other her2 directed therapy.
Beskrivning

Left ventricular ejection fraction | trastuzumab | lapatinib | HER2 Targeted Therapy

Datatyp

boolean

Alias
UMLS CUI [1]
C0428772
UMLS CUI [2]
C0728747
UMLS CUI [3]
C1506770
UMLS CUI [4,1]
C0069515
UMLS CUI [4,2]
C2985566
Tillbaka till toppen

Similar models

Eligibility Breast Cancer NCT02213744

1 Formulär
Name
Typ
Description | Question | Decode (Coded Value)
Datatyp
Alias
Item Group
C1512693 (UMLS CUI)
Invasive carcinoma of breast
Item
patients must have histologically or cytologically confirmed invasive cancer of the breast
boolean
C0853879 (UMLS CUI [1])
Advanced disease Locally | Neoplasm Metastasis | Excision Curative intent Unsuccessful
Item
patients must have documented locally advanced/metastatic disease, defined by the investigator, which is not amenable to resection with curative intent.
boolean
C0679246 (UMLS CUI [1,1])
C1517927 (UMLS CUI [1,2])
C0027627 (UMLS CUI [2])
C0728940 (UMLS CUI [3,1])
C1276305 (UMLS CUI [3,2])
C1272705 (UMLS CUI [3,3])
HER2-positive carcinoma of breast
Item
patients must have her2-positive breast cancer as defined by asco/cap 2013 guidelines that is confirmed by a sponsor-designated central laboratory
boolean
C1960398 (UMLS CUI [1])
Disease Progression | Intolerance to Pertuzumab
Item
patients must have progressed on, or be intolerant to pertuzumab in the labc/mbc setting
boolean
C0242656 (UMLS CUI [1])
C1744706 (UMLS CUI [2,1])
C1328025 (UMLS CUI [2,2])
Disease Progression | Intolerance to Ado-trastuzumab emtansine
Item
patients must have progressed on, or be intolerant to ado-trastuzumab emtansine in the labc/mbc setting
boolean
C0242656 (UMLS CUI [1])
C1744706 (UMLS CUI [2,1])
C2935436 (UMLS CUI [2,2])
Trastuzumab Previous | Pertuzumab Previous
Item
patients must have been previously treated with trastuzumab in any setting (which may have been previously administered with or without pertuzumab)
boolean
C0728747 (UMLS CUI [1,1])
C0205156 (UMLS CUI [1,2])
C1328025 (UMLS CUI [2,1])
C0205156 (UMLS CUI [2,2])
ECOG performance status
Item
ecog performance status of 0 or 1
boolean
C1520224 (UMLS CUI [1])
Item Group
C0680251 (UMLS CUI)
Doxorubicin | doxorubicin liposome | Epirubicin | Mitoxantrone | Anthracycline Derivative
Item
patients who have previously been treated with doxorubicin, liposomal doxorubicin, epirubicin, mitoxantrone, or any other anthracycline derivative
boolean
C0013089 (UMLS CUI [1])
C0717726 (UMLS CUI [2])
C0014582 (UMLS CUI [3])
C0026259 (UMLS CUI [4])
C0282564 (UMLS CUI [5,1])
C1527240 (UMLS CUI [5,2])
CNS metastases | Exception Treatment completed | Exception Stable status Without Symptoms | Exception Steroids Absent
Item
subjects with central nervous system (cns) metastases, unless they have been treated and are stable without symptoms for 4 weeks after completion of treatment and must be off steroids for at least 4 weeks prior to enrollment
boolean
C0686377 (UMLS CUI [1])
C1705847 (UMLS CUI [2,1])
C0580352 (UMLS CUI [2,2])
C1705847 (UMLS CUI [3,1])
C0205360 (UMLS CUI [3,2])
C0332288 (UMLS CUI [3,3])
C1457887 (UMLS CUI [3,4])
C1705847 (UMLS CUI [4,1])
C0038317 (UMLS CUI [4,2])
C0332197 (UMLS CUI [4,3])
Congestive heart failure New York Heart Association Classification | Heart failure with preserved ejection fraction [HFpEF]
Item
patients with any class of new york heart association (nyha) chf or heart failure with preserved ejection fraction (hfpef)
boolean
C0018802 (UMLS CUI [1,1])
C1275491 (UMLS CUI [1,2])
C4509226 (UMLS CUI [2])
Coronary Artery Disease | Myocardial Infarction
Item
patients with a history of known coronary artery disease or a myocardial infarction within the last 12 months
boolean
C1956346 (UMLS CUI [1])
C0027051 (UMLS CUI [2])
Cardiac Arrhythmia Serious Treatment required for | Exception Controlled atrial fibrillation | Exception Paroxysmal supraventricular tachycardia
Item
patients with a known history of serious cardiac arrhythmias requiring treatment (exception: controlled atrial fibrillation, paroxysmal supraventricular tachycardia)
boolean
C0003811 (UMLS CUI [1,1])
C0205404 (UMLS CUI [1,2])
C0332121 (UMLS CUI [1,3])
C1705847 (UMLS CUI [2,1])
C0577699 (UMLS CUI [2,2])
C1705847 (UMLS CUI [3,1])
C0030590 (UMLS CUI [3,2])
Trastuzumab Discontinued Due to Cardiotoxicity
Item
patients who previously discontinued trastuzumab due to unacceptable cardiac toxicity
boolean
C0728747 (UMLS CUI [1,1])
C1444662 (UMLS CUI [1,2])
C0678226 (UMLS CUI [1,3])
C0876994 (UMLS CUI [1,4])
Left ventricular ejection fraction | trastuzumab | lapatinib | HER2 Targeted Therapy
Item
patients with a history of lvef decline to below 50% during or after prior trastuzumab/lapatinib or other her2 directed therapy.
boolean
C0428772 (UMLS CUI [1])
C0728747 (UMLS CUI [2])
C1506770 (UMLS CUI [3])
C0069515 (UMLS CUI [4,1])
C2985566 (UMLS CUI [4,2])
Tillbaka till toppen 

Kontakt

Använd detta formulär för feedback, frågor och förslag på förbättringar.

Fält markerade med * är obligatoriska.

Hjälp

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial